Evidence map›Paper›PMID 38476774›Full record

ArticleJAC-antimicrobial resistance2024

Defining the pharmacokinetic/pharmacodynamic index of piperacillin/tazobactam within a hollow-fibre infection model to determine target attainment in intensive care patients.

Suzanne A M Wenker, Najla Alabdulkarim, John B Readman, Elise M A Slob, Giovanni Satta, Shanom Ali, Nishma Gadher, Rob Shulman, Joseph F Standing

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JAC-antimicrobial resistance, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.4field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 3 countries.

Suzanne A M WenkerInfection, Immunity and Inflammation Department, Great Ormond Street Institute of Child Health, University College London, London, UK.
Najla AlabdulkarimInfection, Immunity and Inflammation Department, Great Ormond Street Institute of Child Health, University College London, London, UK.
John B ReadmanInfection, Immunity and Inflammation Department, Great Ormond Street Institute of Child Health, University College London, London, UK.
Elise M A SlobDepartment of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden University, Leiden, The Netherlands.
Giovanni SattaDepartment of Infection, University College London Hospitals NHS Foundation Trust, London, UK.ORCID https://orcid.org/0000-0002-0120-7885
Shanom AliEnvironmental Research Laboratory, University College London Hospitals NHS Foundation Trust, London, UK.
Nishma GadherPharmacy Department, CMORE, University College London Hospitals NHS Foundation Trust, London, UK.
Rob ShulmanPharmacy Department, CMORE, University College London Hospitals NHS Foundation Trust, London, UK.
Joseph F StandingInfection, Immunity and Inflammation Department, Great Ormond Street Institute of Child Health, University College London, London, UK.ORCID https://orcid.org/0000-0002-4561-7173
University College London Hospitals NHS Foundation Trust · GBGreat Ormond Street Hospital · GBLeiden University Medical Center · NLPrincess Nourah bint Abdulrahman University · SA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: It is important to optimize dosing schemes of antibiotics to maximize the probability of therapeutic success. The recommended pharmacokinetic/pharmacodynamic (PK/PD) index for piperacillin/tazobactam therapy in clinical studies ranges widely (50%-100% Objectives: The first aim of this study was to define the optimal PK/PD index of piperacillin/tazobactam with a hollow-fibre infection model (HFIM). The second aim was to predict whether these PK/PD targets are currently achieved in critically ill patients through PK/PD model simulation. Patients and methods: A dose-fractionation study comprising 21 HFIM experiments was performed against a range of Gram-negative bacterial pathogens, doses and infusion times. Clinical data and dose histories from a case series of nine patients with a known bacterial infection treated with piperacillin/tazobactam in the ICU were collected. The PK/PD index and predicted plasma concentrations and therefore target attainment of the patients were simulated using R version 4.2.1. Results: Conclusions: Our dose-fractionation study indicates an optimal PK/PD target in piperacillin/tazobactam therapies should be 77%

Identifiers

PMID38476774
PMCPMC10928666
OpenAlexW4392709006

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.